menu
    • menu
    [{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"Il-2 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Autotelic BIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabedersen","moa":"TGF beta","graph1":"Oncology","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Autotelic BIO","highestDevelopmentStatusID":"4","companyTruncated":"Mateon Therapeutics \/ Autotelic BIO"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"Il-2 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Not Applicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Not Applicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Not Applicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Divestment","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Not Applicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Aulos \/ Apple Tree Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Apple Tree Partners"},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Not Applicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Not Applicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Merck KGaA","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Merck KGaA"}]

    Find Clinical Drug Pipeline Developments & Deals for Aldesleukin

    Menu

    Aldesleukin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aulos Bioscience Partners with Merck KGaA to Study Bavencio® with AU-007

                            Details : Merck KGaA will provide Aulos a free supply of Bavencio to evaluate in combination with AU-007, which is being under clinical investigation for the treatment of solid tumor cancers.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aulos Doses First Patient in Phase 2 Trial for IL-2 Antibody for Solid Tumors

                            Details : AU-007 is an IgG1 monoclonal antibody leveraging IL-2 to eradicate solid tumors, currently in phase 1/2 trials for advanced melanoma and renal cell carcinoma.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 25, 2024

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-...

                            Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. It is under phase 1/2 clinical development for the treatment of solid tumors.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Apple Tree Partners

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Aulos Bioscience Raises $20 Million in Series A Extension Financing from Apple Tree Partners

                            Details : The funds will be used to advance Aulos’ lead human monoclonal antibody candidate, AU-007 that is highly selective to the CD25-binding portion of IL-2, through its initial Phase 2 clinical study in solid tumor cancers.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Apple Tree Partners

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic ...

                            Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor ...

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Clinigen Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : $206.3 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Clinigen Divests Proleukin® to Iovance Biotherapeutics for £166.7 million

                            Details : Proleukin® (aldesleukin), a form of interleukin-2, is indicated for the treatment of adults with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC).

                            Brand Name : Proleukin

                            Molecule Type : Large molecule

                            Upfront Cash : $206.3 million

                            January 23, 2023

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : $206.3 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Clinigen Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin,Riluzole

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinigen Notes Results from The MIROCALS Trial Investigating Low Dose Proleukin® (aldesleukin) In Patients wi...

                            Details : Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.

                            Brand Name : Proleukin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : Aldesleukin,Riluzole

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ImCheck Therapeutics

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ImCheck Therapeutics

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICT01,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

                            Details : The combination also demonstrated the activation, mobilization, and proliferation of CD8 T cells and NKs, with slightly more modest effects on granulocytes, in most patients at lower ICT01 doses than shown in previously presented data of ICT01 monotherap...

                            Brand Name : ICT01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 11, 2022

                            Lead Product(s) : ICT01,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeut...

                            Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2.AU-007 leverages IL-2 to reinforce anti-tumor immune effects.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aulos

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 ...

                            Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor ...

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth